Bora Pharmaceuticals Exits Integration Phase with Sequentially-Improved Gross and Operating Margins
HONG KONG SAR - Media OutReach Newswire - 14 May 2025 - Bora Pharmaceuticals (TWSE: 6472) today announced its financial results and operational highlights for first quarter of 2025.
Quarterly Business and Financial Highlights
Fueled by expanded capacity and new dosage forms, Bora's CDMO business delivered a record high quarter, up 52.4% YoY and 3.0% QoQ.
As part of Bora's long-term strategic growth plan, the Company is moving forward with a phased investment of tens of thousands US dollars to unlock the untapped potential of Maple Grove facility. This build-out is designed to enhance capabilities in oral solid dose and sterile manufacturing, strengthening the ability to support customer demand and scale future programs.
Pharma Sales revenues rose 82.0% YoY based on reported unaudited monthly sales, driven by strong performance from the vigabatrin franchise, which includes three dosage forms. Notably, VIGAFYDE captured over 70% share in the new patient segment.
Due to the completion of Plymouth area decommissioning, consolidated revenues for 1Q25 was NT$4.48 billion, a NT$350 million reversal from the unaudited monthly disclosures, all of which was attributed to the pharma sales segment.
Despite margin pressure from partial maintenance shutdowns at the Maryland sterile injectable site in early January and softening demand for generic product dexlansoprazole (DLS), product mix improvement from growing specialty portfolio lifted gross margin from the low of 4Q24 to 42.2% in 1Q25. Tech transfer for 6 Upsher-Smith generic products to cost-competitive sites within Bora network remains on track, with full transfer expected by year-end to support further margin recovery.
EPS from continuing operations reached NT$26.54, reflecting NT$2.44 billion of net non-operating income from the divestment of Bora Biologics and recognition of losses of Tanvex Biopharm. However, the decommissioning of the Plymouth area negatively impacted EPS by NT$12.99, resulting in a reported EPS of NT$13.55. Share capital increased 0.4% during the quarter from employee stock option exercises and convertible bond conversions.
DLS competitors began exiting the market in early 2Q25 due to supply chain hiccups, creating new opportunities for Bora to increase share and drive recovery momentum.
The Group remains optimistic that its first quarter restructuring efforts will increase the long-term value of its recent acquisitions, including unlocking NT$600 million in capital in 2025. CDMO business growth will be further accelerated with strategic U.S.-based capability and capacity.
Mr. Bobby Sheng, Chairman of Bora Group, stated, "The first quarter is the continuation of critical integration and restructuring phase following multiple business and capacity acquisitions in 2024, laying a solid foundation for operational efficiency expansion. Following substantial investments in the U.S last year, we did observe significant pressure in the U.S. generics space during Q4. This prompted us to swiftly accelerate our integration efforts. At the same time, evolving client dynamics and market demand have only strengthened our conviction in the long-term value and strategic role of these assets. While the organizational streamlining, business separation, and product portfolio optimization undertaken to reflect operational realities have created near-term hurdles, we remain confident that these actions are essential to achieving optimal resource allocation and hence satisfactory return on assets. These efforts are necessary steps in the Company's path toward sustainable mid to long-term growth.
The closure of Plymouth area was completed ahead of schedule during the quarter and the area has thus been reclassified as discontinued operation in our quarterly financial statements altogether. From an operational standpoint, Bora has discontinued 15 products in the U.S. generics market along with the restructure, with an additional 6 products transferred to more cost-efficient manufacturing sites within the Group. On the financial side, discontinued operation resulted in a negative impact of approximately NT$1.34 billion, including overhead, inventory and equipment write-downs as well as severance-related expenses.
Looking ahead, Bora will advance its focus on high-value and complex dosage forms supported by over NT$5.0 billion cash on hand. At Maple Grove, 4 global pharmaceutical clients are currently in advanced discussions regarding CAPEX investments which we view as a strong validation of the site's value and strategic fit. While the timeline for full deployment spans several years, we are approaching this expansion with operational discipline and commercial alignment to ensure its success over time.
On pharma sales side, Bora weathered softness in DLS demand in the first quarter but quickly gained market share as a competitor exited in early second quarter. Generic business rebounded in April, supported by strong sales from new 2024 launches including Potassium Chloride ER Tablets (KCL), and anti-angina drugs Diltiazem (DTC and DTS). This recovery underscores Bora's agility and the resilience of the dual-engine strategy. Furthermore, we have successfully consolidated distribution network for specialty drugs. Bora expects its pediatric spasm product, VIGAFYDE (the 505(b)(2) oral solution), to extend its success in the new patient market into the switch segment in the very near future, supporting future margin and operational leverage expansion.
We continue executing on our goals to scale up, achieve more and integrate smarter, ensuring that both internal and external clients benefit from cost-efficient, regionally aligned manufacturing. By extending the strength of our dual-engine model, we believe Bora shall continue to create above-average total shareholder return."
1Q2025 Operational Achievements & Full Year Outlook
Global CDMO Operations
Global CDMO Operations (excluding internal orders) delivered record-high revenues of NT$1.90 billion in the first quarter, up 52.4% YoY and representing approximately 39% of total revenue. Including internal orders, CDMO revenue reached NT$2.89 billion. A total of 600 million doses were developed and manufactured. Revenue contribution from global top 20 pharmaceutical companies remained steady at approximately 30%, demonstrating strong clientele and advantage of scale. Bora CDMO continues to be a trusted partner for biotech and pharmaceutical innovators.
In 1Q25, the small molecule CDMO pipeline added US$123 million in potential orders and US$78 million in backlog, both marking historic highs.
CAPEX progress across sites reached approximately 50%, focused on debottlenecks, efficiency improvement, capacity increase and infrastructure upgrade to align with client and product needs. Flex Pro line at the Maryland sterile injectable facility was completed ahead of schedule and is expected to begin operations in early Q3.
Maple Grove launched its first CDMO project during the quarter and is currently negotiating with potential clients while evaluating CAPEX plans for differentiated dosage platforms. Overall, North American capacity transformation is progressing as planned.
Large molecule CDMO operation was launched following the January 20 reverse-acquisition of Bora Biologics by Tanvex Biopharm where Bora owns 30.5% of Tanvex. CDMO operations at the San Diego site are now active, and the ongoing 2,000L expansion has received strong interest from late-stage clients. Bora and Tanvex are actively pursuing U.S.-based commercial-scale manufacturing orders with a comprehensive one-stop service model.
Pharma Sales Operations
Pharma Sales Operations revenue reached NT$2.93 billion, representing 82.0% YoY growth and contributing approximately 61% of total revenue based on unadjusted numbers.
As the Upsher-Smith team continue to consolidate distributors for specialty drugs, we saw early signs of positive engagement from both market and payer channels at the end of the first quarter. Following the 2024 integration of TWi, Upsher-Smith and Pyros teams, Bora has established a focused pipeline in CNS specialty areas. The company expects to file its first self-developed 505(b)(2) submission for infantile spasms (Stiripentol) with the U.S. FDA by year-end, alongside other pipeline developments.
Pediatric epilepsy and TSC-related rare diseases represent the first wave of Bora's pharma sales transformation targets. In addition to reducing over-reliance on generics, high-value rare disease and specialty drugs benefit from strong regulatory and payer support in the specialty pharmacy channel. These markets are less competitive with stable price, and offer targeted access to patient populations, allowing for meaningful long-tail value creation.
Recent Investor Conference
Bora will host an English online earnings call at 7:00 a.m. Taiwan time on May 15, 2025, followed by an investor conference hosted by Taishin Securities at the Grand Hyatt Taipei at 2:00 p.m. on May 16, 2025. Both events will cover the company's Q1'25 financial and business results and outlook.
English Online Earnings Presentation Link: https://www.zucast.com/event/54SiM5il/subscribe/create
The 2025 Annual General Shareholders' Meeting will be held on May 23 at the Tainan Guantian Industrial Marketing Center.
Bora will participate in the Jefferies Global Healthcare Conference in New York on June 4–5. For 1:1 meetings with management, please contact your Jefferies representative.
Bora 2025 Earnings Schedule
Q2 2025: Expected in the 3 rd week of August 2025
Q3 2025: Expected in the 3 rd week of November 2025
Q4 2025: Expected in the 2 nd week of March 2026
Hashtag: #Bora
The issuer is solely responsible for the content of this announcement.
About Bora
Founded in 2007, Bora Pharmaceuticals ("Bora" or "the Company", 6472.TW) is a leading pharmaceutical services company with a vision and goal of "Contributing to Better Health All Over the World". Operating under a "Dual Engine" model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients' quality of life.
By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success "certain," Bora sets new standards in the pharmaceutical and CDMO industries.
For more, please visit:
https://www.bora-corp.com
Disclaimer:
This document and the accompanying information may contain forward-looking statements. All statements regarding the company's future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company's control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.
Bora Pharmaceuticals
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
16 minutes ago
- Zawya
Shop Smarter in Macau: ShopBack Debuts with Exclusive Cashback Rewards Across Leading Merchants
HONG KONG SAR - Media OutReach Newswire - 1 August 2025 - ShopBack, Asia's foremost cashback platform, proudly announces its official entry into the Macau market, introducing a sophisticated yet intuitive solution for savvy shoppers to unlock greater value with every transaction. This strategic expansion signifies ShopBack's commitment to bringing its signature savings-driven shopping experience to a new community of users. With the official launch now underway, residents of Macau are invited to register via the ShopBack website or mobile app and immediately begin enjoying seamless cashback benefits across a diverse range of renowned merchants. From travel bookings to fashion essentials, personal care, and lifestyle products, ShopBack empowers users to earn cashback on purchases that already form part of their everyday lives. At the heart of this initiative lies ShopBack's enduring philosophy: " If it's not a steal, it's not a ShopBack Deal"—a reflection of its mission to champion smart consumption and redefine online shopping through the lens of genuine value. ShopBack welcomes all Macau residents starting August 2025 to participate without minimum spend requirements or hidden conditions. Users can explore well-known travel platforms including Agoda, Expedia, KKday, HopeGoo, and Wing On Travel, as well as retail and lifestyle favorites such as Nike, Watsons, iHerb, Farfetch, Selfridges, Net-A-Porter, Sasa, and Sephora, with cashback seamlessly credited upon merchant confirmation. Withdrawals are effortlessly processed via FPS, ensuring a smooth and immediate reward experience. ShopBack's Macau debut also introduces an innovative twist to its value proposition through ShopBack Play —a gamified feature within the ShopBack app where users can download curated mobile games and earn cashback simply by engaging with them. This " Play to Earn" model adds a layer of entertainment to the shopping journey and further strengthens the brand's resonance with a digitally engaged audience. This milestone sets a new standard for consumer engagement in the region and reinforces ShopBack's reputation as the go-to platform for shrewd, rewarding, and hassle-free online shopping. Mr. Arthur Wan, General Manager of Hong Kong & Taiwan at ShopBack, stated: "ShopBack's arrival in Macau marks a strategic advancement in our mission to reshape how consumers engage with e-commerce platforms across Asia. We're proud to empower Macau residents with a seamless and rewarding experience, where every purchase unlocks real and measurable value. This launch underscores our commitment to marketing innovation, business growth, and customer-centric technology, delivering not just rebates, but a smarter way to shop." Hashtag: #ShopBack The issuer is solely responsible for the content of this announcement. About ShopBack ShopBack is Asia's leading cashback platform, offering users an easy and seamless way to earn cashback on purchases. Simply shopping through ShopBack's app allows users to receive cashback directly into their ShopBack account upon completing their orders and merchant confirmation. Cashback withdrawals are seamlessly processed via FPS or transferred to cash dollars, ensuring instant accessibility for travel bookings, dining experiences, and shopping purchases, allowing users to enjoy their rewards effortlessly and smoothly. To start earning rewards and explore everything ShopBack Macau has to offer, visit: ShopBack
The National
an hour ago
- The National
US tariffs on dozens of countries to take effect in seven days, executive order says
US President Donald Trump signed an executive order on Thursday imposing ' reciprocal tariffs ' ranging from 10 per cent to 41 per cent on dozens countries. The levies will take effect in seven days, the order said. For Middle East countries, Syria received one the heaviest tariffs at 41 per cent, as did Iraq at 35 per cent and Libya at 30 per cent. Jordan and Israel were both hit with 15 per cent. Trading partners not listed in Friday's executive order will be subject to a duty of 10 per cent. The White House said that Canada's tariffs would be raised to 35 per cent due to its 'continued inaction and retaliation'. But the US will keep in place an exemption for goods traded under the rules of the US-Mexico-Canada trade agreement. The executive order highlighted that certain foreign trading partners have agreed to, or were on the verge of concluding, 'meaningful trade and security agreements with the United States'. 'Goods of those trading partners will remain subject to the additional ad valorem duties provided … to this order until such time as those agreements are concluded,' it said. Mr Trump announced the so-called retaliatory tariffs, which Washington says are aimed at addressing trade imbalances, in April. He then enacted a series of pauses to allow for trade negotiations. In recent weeks, the President has sent out dozens of letters to countries around the world inviting them to negotiate trade deals or be subject to tariffs. The US has recently struck deals with the EU, the UK, Japan and South Korea. 'President Trump is using tariffs as a necessary and powerful tool to put America First after many years of unsustainable trade deficits that threaten our economy and national security,' the White House said in a fact sheet.
Khaleej Times
7 hours ago
- Khaleej Times
US inflation warms up in June as tariffs boost some goods prices
U.S. inflation increased in June as tariffs boosted prices for imported goods like household furniture and recreation products, supporting views that price pressures would pick up in the second half of the year and delay the Federal Reserve from resuming cutting interest rates until at least October. The report from the Commerce Department on Thursday showed goods prices last month posting their biggest gain since January, with also solid rises in the costs of clothing and footwear. The U.S. central bank on Wednesday left its benchmark interest rate in the 4.25%-4.50% range and Fed Chair Jerome Powell's comments after the decision undercut confidence the central bank would resume policy easing in September as had been widely anticipated by financial markets and some economists. "The Fed is unlikely to welcome the inflation dynamics currently taking hold," said Olu Sonola, head of U.S. economic research, Fitch Ratings. "Rather than converging toward target, inflation is now clearly diverging from it. This trajectory is likely to complicate current expectations for a rate cut in September or October." The personal consumption expenditures (PCE) price index rose 0.3% last month after an upwardly revised 0.2% gain in May, the Commerce Department's Bureau of Economic Analysis said. Economists polled by Reuters had forecast the PCE price index climbing 0.3% following a previously reported 0.1% rise in May. Prices for furnishings and durable household equipment jumped 1.3%, the biggest gain since March 2022, after increasing 0.6% in May. Recreational goods and vehicles prices shot up 0.9%, the most since February 2024, after being unchanged in May. Prices for clothing and footwear rose 0.4%. Outside the tariff-sensitive goods, prices for gasoline and other energy products rebounded 0.9% after falling for four consecutive months. Services prices rose 0.2% for a fourth straight month, restrained by cheaper airline fares and steady prices for dining out and hotel stays. In the 12 months through June, the PCE price index advanced 2.6% after increasing 2.4% in May. The data was included in the advance gross domestic product report for the second quarter published on Wednesday, which showed inflation cooling, though remaining above the Fed's 2% target. Economists said businesses were still selling inventory accumulated before President Donald Trump's sweeping import duties came into effect. They expected a broad increase in goods prices in the second half. Procter Gamble said this week it would raise prices on some products in the U.S. to offset tariff costs. The Fed tracks the PCE price measures for monetary policy. Excluding the volatile food and energy components, the PCE price index increased 0.3% last month after rising 0.2% in May. In addition to higher goods prices, the so-called core PCE inflation was lifted by rising costs for healthcare as well as financial services and insurance. In the 12 months through June, core inflation advanced 2.8% after rising by the same margin in May. Stocks on Wall Street were mixed. The dollar was steady against a basket of currencies. U.S. Treasury yields fell. Consumer spending steady The BEA also reported that consumer spending, which accounts for more than two-thirds of economic activity, rose 0.3% in June after being unchanged in May. The data was also included in the advance GDP report, which showed consumer spending growing at a 1.4% annualized rate last quarter after almost stalling in the first quarter. In the second quarter, economic growth rebounded at a 3.0% rate, boosted by a sharp reduction in the trade deficit because of fewer imports relative to the record surge in the January-March quarter. The economy contracted at a 0.5% pace in the first three months of the year. Spending is being supported by a stable labor market, with other data from the Labor Department showing initial claims for state unemployment benefits rose 1,000 to a seasonally adjusted 218,000 for the week ended July 26. But a reluctance by employers to increase headcount amid uncertainty over where tariff levels will eventually settle is making it harder for those who lose their jobs to find new opportunities, which could hamper future spending. The number of people receiving benefits after an initial week of aid, a proxy for hiring, was unchanged at a lofty seasonally adjusted 1.946 million during the week ending July 19, the claims report showed. The government's closely watched employment report on Friday is expected to show the unemployment rate rising to 4.2% in July from 4.1% in June, according to a Reuters survey of economists. Economists expect pressure from tariffs and a slowing labor market will put a brake on consumer spending in the third quarter. Slow growth is likely already in the works as inflation-adjusted consumer spending edged up 0.1% in June after declining 0.2% in May. Precautionary saving could also curb spending. The saving rate was unchanged at 4.5% in June. Though a third report from the Labor Department showed wage growth picking up in the second quarter, inflation-adjusted annual gains moderated to 0.9% from 1.1% in the 12 months through March. The BEA report showed inflation cutting into income for households after accounting for taxes, which was flat in June. Signs of financial strain are also emerging among higher-income households, who have largely been driving spending. Lower- and middle-income families have been disproportionately affected by tariff-related price increases, higher borrowing costs and slowing economic activity. "While consumer spending has thus held up — supported by solid income gains — it now faces mounting headwinds from a cooling labor market and renewed inflationary pressures," said Gregory Daco, chief economist at EY-Parthenon.
